Approval Package for:

APPLICATION NUMBER: 210605Orig1s000

Trade Name: Semglee for subcutaneous use (insulin glargine injection)

Generic or Proper Name: (insulin glargine injection)

Sponsor: Mylan Pharmaceuticals Inc.

Approval Date: June 11, 2020

Indication: Provides for the use of Semglee (insulin glargine injection) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
## Reviews / Information Included in this NDA Review

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td>X</td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td>X</td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Clinical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Non-Clinical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
210605Orig1s000

APPROVAL LETTER
Dear Mr. Talton:

Please refer to your new drug application (NDA) dated and received April 27, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Semglee (insulin glargine injection).

We acknowledge receipt of your amendment dated December 16, 2019, which constituted a complete response to our August 28, 2019, action letter.

This new drug application provides for the use of Semglee (insulin glargine injection) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.1

Content of labeling must be identical to the enclosed labeling (text for the

1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
Prescribing Information, Patient Package Inserts, and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling and carton and container labeling submitted on March 11, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission "Final Printed Carton and Container Labeling for approved BLA 210605."³ Approval of this submission by FDA is not required before the labeling is used.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

³ Upon approval, this approved NDA will be deemed to be an approved biologics license application (BLA) under section 351(a) of the Public Health Service Act (see section 7002(e)(4)(B)(iii) of the Biologics Price Competition and Innovation Act of 2009).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs. 4

As required under 21 CFR 314.81(b)(3)(i) (upon approval, under 21 CFR 601.12(f)(4)), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov. 5 Information and Instructions for completing the form can be found at FDA.gov. 6

REPORTING REQUIREMENTS

Upon approval, this approved NDA will be deemed to be an approved biologics license application (BLA) under section 351(a) of the Public Health Service Act (see section 7002(e)(4)(B)(iii) of the Biologics Price Competition and Innovation Act of 2009). Accordingly, we remind you that upon approval, you will be required to comply with reporting requirements for an approved BLA (21 CFR 600.80, 600.81, and 600.14)

If you have any questions, call Michael G. White, Ph.D., Senior Regulatory Project Manager, at (240) 402-6149.

Sincerely,

{See appended electronic signature page}

Patrick Archdeacon, M.D.
Associate Director for Therapeutics (Acting)
Division of Diabetes, Lipid Disorders, and Obesity
Office of Cardiology, Hematology, Endocrinology, and Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Instructions for Use
- Carton and Container Labeling

---

4 For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
6 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

PATRICK ARCHDEACON
06/11/2020 10:43:54 AM

Reference ID: 4623030